Reset Pharma partners with Filament to license psilocybin drug

Reset Pharma has entered a licensing agreement with Filament for psilocybin drug PEX010, designed for treating demoralisation syndrome.

Sep 1, 2023 - 20:00

Reset Pharma partners with Filament to license psilocybin drug

Reset Pharma has entered a licensing agreement with Filament for psilocybin drug PEX010, designed for treating demoralisation syndrome.

Read the original article

Tags:

Previous Article

The changing of the guard is expected in the Crohn’s disease marketplace

Huadong enters licence deal for MC2 Therapeutics’ Wynzora cream

What's Your Reaction?

0

Like

0

Dislike

0

Love

0

Funny

0

Angry

0

Sad

0

Wow

Related Posts

LEO-152020 by Leo Pharma for Atopic Dermatitis (Atopic ...

Oct 29, 2023

Sensorion raises $16m for gene therapies to treat deafness

Sensorion raises $16m for gene therapies to treat deafness

Apr 9, 2024

AD/PD 2024: TauRx’s HMTM promising despite lacking primary endpoint data

AD/PD 2024: TauRx’s HMTM promising despite lacking prim...

Mar 9, 2024